Blaize Holdings enters the post-earnings period carrying a 30% weekly loss, a revenue shortfall that dwarfs a guidance reaffirmation, and insiders who have been selling on the way down.
The Q1 print on May 14 was the week's defining event. EPS of -$0.19 beat the -$0.21 estimate, but the revenue number landed at $2.7M against a $10.1M consensus — a miss of roughly 73%. Despite that, management held the FY2026 revenue guide at $130M, a figure that now implies a very steep ramp over the remaining three quarters. The stock dropped 21.8% the day after the release, extending a one-month decline of 26%. At $1.31, the share price is now roughly a third of the mean analyst price target of $4.88, a gap that warrants flagging: while all four covering analysts maintain Buy ratings, B. Riley cut its target from $8 to $5 in March, and DA Davidson held at $3 as of late April. The Street is bullish in rating, but targets have been drifting lower as execution has disappointed.
Short interest added another layer of pressure. At 11.9% of free float as of May 14, short interest is running near the upper end of the six-week range. It spiked 12% in a single day on May 14 — the earnings date — after spending most of the prior two weeks declining from a peak above 14% of free float in late April. The availability picture tells a nuanced story. Through late April and early May, availability was extremely tight, with utilisation repeatedly hitting 100% and shares nearly impossible to borrow. That has eased somewhat: availability is now less constrained at roughly 22% of short interest, borrowing costs have pulled back to 3.25% from a recent high near 5.1% in early May. The borrow market has loosened in the wake of the price collapse, but short interest is rebuilding again.
Options positioning does not add much urgency to the bearish thesis. The put/call ratio of 0.07 is barely above its 20-day average of 0.066, suggesting options traders have not moved to hedge more aggressively. This is a low-liquidity name in the options market, and the near-zero z-score (0.42) confirms there is no unusual defensive positioning in the options data. The ORTEX short score of 65.8 is notable: it ranks in the 5th percentile for its sector, meaning short pressure is more intense here than for almost all sector peers.
Insider activity has been uniformly bearish in recent weeks. The CFO sold shares twice — in late April and early May — realising a combined ~$161K at prices of $1.97–$2.28. The founder and CEO sold 50,000 shares at $2.54 in mid-April. A director sold 50,000 shares as recently as May 11, at $1.85. These are modest transaction sizes in dollar terms, but the pattern is consistent: every C-suite and board transaction over the past six weeks has been a sale, with no purchases. The 90-day net is technically positive due to an award in early April, but the open-market selling direction is uniformly one way.
The bull case rests on the $130M guidance hold, a $50M NeoTensr AI infrastructure contract announced in April, and partnerships with Winmate and Datacomm targeting defence and emerging-market AI inference. Bears point to severe execution risk — Q1 revenue of $2.7M implies the company must deliver roughly $127M across Q2–Q4 to meet its own guide — plus customer concentration, competitive pressure from larger AI hardware names, and a rights plan adopted in late April that expires in April 2027, which itself signals the board is watching the share price closely.
The next material datapoint is whether management provides any intra-quarter update on contract ramp timing; the gap between the guidance hold and actual delivered revenue is now wide enough that the market will need more than a quarterly print to bridge it.
See the live data behind this article on ORTEX.
Open BZAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
